Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors
FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors
The FDA has cleared an investigational new drug (IND) application for the TROP-2 targeted antibody drug conjugate (ADC), OBI-902, to conduct a phase 1/2 study in patients with solid tu...
Scientists at the University of East Anglia (UEA) have developed a revolutionary new way
Scientists at the University of East Anglia (UEA) have developed a revolutionary new way
Scientists at the University of East Anglia (UEA) have developed a revolutionary new way of uncovering the 'true age' of your heart using MRI
Dimerix and Amicus to commercialise DMX-200 in US
Dimerix and Amicus to commercialise DMX-200 in US
Australian biopharmaceutical company Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug candidate DMX-200.
Silo Pharma's SP-26
Silo Pharma's SP-26
Silo Pharma's SP-26 Implant Achieves All Endpoints In Preclinical Fibromyalgia Study
NewAmsterdam Pharma
NewAmsterdam Pharma
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with borderline personality disorder (BPD) using new tech...
Abeona cell therapy approved by FDA for rare skin condition
Abeona cell therapy approved by FDA for rare skin condition
The Food and Drug Administration on Tuesday approved a new treatment for a rare skin condition, teeing up a commercial battle between two cell and gene therapy developers.
Nuvalent reveals preclinical data on cancer drug zidesamtinib
Nuvalent reveals preclinical data on cancer drug zidesamtinib
CAMBRIDGE, Mass. - Nuvalent, Inc., a clinical-stage biopharmaceutical company valued at $5.4 billion
Amgen to invest $900m in Ohio manufacturing facility
Amgen to invest $900m in Ohio manufacturing facility
Amgen has announced a significant expansion of a manufacturing facility in the US state of Ohio, with an investment of $900m.
AbbVie Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis
AbbVie Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis
AbbVie  recently secured FDA approval for RINVOQ (Upadacitinib) to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company&...
Portage Biotech Reports Confirmatory Preclinical Results
Portage Biotech Reports Confirmatory Preclinical Results
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial
Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial
Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand